UBS Raises BrightSpring Target to $42, Reiterates Buy After Third Quarter Beat-and-Raise
BrightSpring Health Services, Inc. (NASDAQ: BTSG) is one of the best digital health stocks to buy now.
On October 29, a day after releasing third-quarter results, UBS analyst AJ Rice. reiterated Buy and raised its 12-month price target to $42 (from $35), citing a classic “beat and rise” quarter and management confidence, particularly around specialty/infusion dynamics through 2026.
On October 28, BrightSpring Health Services, Inc. (NASDAQ: BTSG) reported revenue of $3.334 billion (+28.2% YoY), adjusted EBITDA of $160 million (+37.2% YoY), and net income of $37.5 million compared to a loss in the prior year.
Photographee.eu/Shutterstock.com
The mix did the heavy lifting: Pharmacy Solutions grew about 31% to $2.97 billion in specialty and infusion power, while Provider Services grew about 9% to $367 million. Management raised its FY25 revenue guidance to between $12.4 billion and $12.7 billion and maintained adjusted EBITDA between $605 million and $615 million, highlighting continued specialty volume, limited distribution drug additions and execution across the pharmaceutical platform.
BrightSpring Health Services, Inc. (NASDAQ: BTSG) is a post-acute care company providing home and community clinical services, as well as pharmacy solutions, across the United States. It serves medically complex and aging populations through a combination of home care, behavioral health support and medication management.
While we recognize the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for a hugely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the reshoring trend, check out our free report on the best AI stock in the short term. READ NEXT: 30 stocks that should double in 3 years And 11 Hidden AI Stocks to Buy Right Now. Disclosure: None.
